近日，杭州智诊科技有限公司（以下简称"智诊科技"）与腾讯云在2025腾讯云城市峰会无锡峰会期间正式签署战略合作协议。双方将在"AI+医疗健康"领域 展开深度合作，凭借智诊科技的技术优势和腾讯云的数字化技术及生态产品，共同构建开放、安全的AI医疗基础设施，推动智慧医疗的落地与普惠应用。 在智诊科技首席运营官王锋，腾讯云副总裁、产业生态合作业务负责人杨晨，智诊科技产品总监罗龙生，腾讯云渠道售前总经理尹晟宇，腾讯云东区渠道总 经理徐泳泽等的共同见证下，智诊科技市场总监惠靖博与腾讯云东区渠道总监尤仙仙代表双方签署战略合作协议。 此次合作不仅是双方技术与资源的高度互补，也将携手迈向以"AI+医疗健康"为核心的全新发展阶段。未来，智诊科技与腾讯云将持续深化合作，共同构建 开放、安全、智能的医疗健康服务体系，让AI医疗惠及更多民众。 来源：鲁网 在大模型训练方面，腾讯云将基于高性能算力基础设施、星脉高性能计算网络、CFS Turbo存储与AI原生算力平台，为智诊科技提供高效、稳定的模型训练 与推理环境，保障 WiseDiag 大模型的持续优化与快速迭代。 在生态协同方面，腾讯云将依托微信及企业微信的生态连接能力，助力智诊科 ...

Core Insights - The company reported a stable total revenue of 358 million yuan for the first half of the 2026 fiscal year, reflecting a year-on-year growth of 8.7% [1] - Significant progress has been made in the "AI + Public Health" layout, with services covering nearly 30 provinces and cities, and 44 healthcare regulatory agencies [1] - The company has established 27 million resident health records, creating a solid public health service network [1] Financial Performance - The quality of earnings has significantly improved, with adjusted EBITDA doubling year-on-year to 54 million yuan, nearing breakeven on the financial statements [1] - The company achieved this financial milestone a year ahead of management expectations [1] - New orders in the big data platform and life sciences solutions segments grew by 19.7% and 61.1% respectively, providing ongoing momentum for future development [1] Strategic Positioning - The company is deeply involved in the construction of the National AI Application Center in the medical field in Beijing, highlighting its important role in national-level medical AI projects [1] - This strategic positioning aligns with the company's large model technology entering the "scale landing" phase, showcasing the integration of technological innovation with public service [1] - The report indicates that the company is effectively combining its technological advantages with public service needs, expanding the social value boundaries of medical AI while achieving commercial value [1]

天眼查信息显示，江苏臻亿医疗科技有限公司的股东为：上海桓磊医疗科技服务中心（有限合伙）、如 东生命树创业投资合伙企业（有限合伙）、上海揽腾医疗科技服务中心（有限合伙）、苏州济峰三号股 权投资合伙企业（有限合伙）、厦门建发新兴产业股权投资贰号合伙企业（有限合伙）。 来源：市场资讯 资料显示，江苏臻亿医疗科技有限公司法定代表人为闻靖，成立于2019年，位于南通市，是一家以从事 研究和试验发展为主的企业。企业注册资本2628.7818万人民币，并已于2025年完成了C轮，交易金额数 亿人民币。 通过天眼查大数据分析，江苏臻亿医疗科技有限公司共对外投资了8家企业，知识产权方面有商标信息 25条，专利信息77条，此外企业还拥有行政许可24个。 11月28日消息，天眼查融资历程显示，江苏臻亿医疗科技有限公司近日获得"C轮"融资，涉及融资金额 数亿人民币，投资机构为东方富海，国元股投，厦门创投，厦金创新私募基金，博正资本，思明科创， 生命树资本。 ...

Core Insights - Yidu Technology reported a total revenue of RMB 358 million for the first half of the 2026 fiscal year, representing an 8.7% year-on-year growth, with adjusted EBITDA doubling to approximately RMB 54 million [1] - The company has seen significant growth in its core business segments, with new order amounts in the big data platform and solutions segment increasing by 19.7% and the life sciences solutions segment by 61.1% [1] - The management highlighted advancements in AI technology, with applications in over 30 top-tier hospitals and a significant increase in the accuracy of its TNM staging assessment tool [1][2] Business Segment Performance - The big data platform and solutions segment generated revenue of RMB 153 million, a 14.6% increase year-on-year, providing solutions to 127 top hospitals and 44 regulatory bodies [3] - The life sciences solutions segment achieved revenue of RMB 138 million, supporting the accelerated approval of several innovative drugs and gaining recognition in real-world research [4] - The health management platform and solutions segment reported revenue of RMB 66.67 million, a 30.3% increase, with significant participation in public health insurance projects and a notable rise in active users [5] Technological Advancements - YiduCore, the company's core algorithm engine, processed over 1.3 billion patient visits and nearly 7 billion authorized medical records, covering over 10,000 hospitals [1] - The company has successfully reduced the incidence of "hallucinations" in AI models to below 1% and improved the accuracy of its TNM staging assessment tool significantly [2] - Yidu Technology received industry recognition at the CHIP 2025 conference, winning awards for its advancements in medical NLP [2]

Core Insights - The company reported a revenue increase of 8.7% year-on-year, reaching 358.1 million RMB for the six months ending September 30, 2025 [1] - Revenue from the big data platform and solutions grew by 14.6%, while revenue from the health management platform and solutions surged by 30.3% [1] Company Developments - YiduCore, the company's core algorithm engine, continued to advance the research and training of large language models in the medical vertical during the reporting period [1] - The training was based on over 500 billion high-quality tokens and involved the processing and analysis of more than 1.3 billion patient visits, utilizing nearly 7 billion authorized medical records [1] - The company has constructed a dataset system covering over 98 specific diseases [1]

今年7月，好医生集团与杭州全诊医学科技有限公司宣布达成战略合作，并签署了战略合作协议。 同时，好医生集团宣布参与全诊医学新一轮融资，作为战略投资人助推全诊医学快速发展壮大。 好医生集团董事长耿福能表示，这不仅是商业合作，更是好医生集团践行企业社会责任、助力分级诊疗落地的重大举措。（来源：好医生集团） （注：此文属于央广网登载的商业信息，文章内容不代表本网观点，仅供参考） 好医生集团与全诊医学签署战略合作协议（好医生集团供图） 作为战略合作的一部分，好医生集团与全诊医学将通过共同投资成立的合资公司，面向基层医疗市场提供全套医疗管理信息系统（HIS）、医学AI大模型 （LLM）和系列化医疗智能体（Agent）。该合作将深度融合好医生集团覆盖全国基层医疗终端的市场网络与全诊医学领先的人工智能大模型训练、研发 和应用能力，共同致力于为全国基层医疗机构开发和部署AI解决方案，切实提升基层诊疗能力、服务效率和管理水平。 ...

Group 1 - The company Yidu Technology (医渡科技) reported interim results for the six months ending September 30, 2025, with revenue of approximately 358 million yuan, an increase of 8.7% year-on-year; gross profit was about 134 million yuan, up 14.2% year-on-year; and the loss narrowed to 15.76 million yuan, a decrease of 72% year-on-year [1] - The big data platform and solutions segment generated revenue of 153 million yuan, a year-on-year increase of 14.6%, primarily benefiting from expanded business opportunities driven by policy support [1] - The health management platform and solutions segment reported revenue of 66.6 million yuan, a year-on-year increase of 30.3%, mainly due to changes in the product mix [1] Group 2 - YiduCore, the company's core algorithm engine, continued to advance the research and training of large language models in the medical vertical during the reporting period, training on over 500 billion high-quality tokens and analyzing nearly 7 billion authorized medical records from over 1.3 billion patient visits, creating a dataset system covering more than 98 specific diseases [2] - The model won the "Best Paper Award" and the championship in the "Medical NLP Code Auto-Generation Evaluation" at the 11th China Health Information Processing Conference (CHIP 2025) and also secured first place in the medical health track at the 2025 "Data Element ×" competition in Jiangxi [2] - As an important ecological partner in the national artificial intelligence application pilot base in Beijing's medical field, YiduCore achieved large-scale deployment across medical, pharmaceutical, and health insurance sectors through a "one base, multiple applications" model, fully implementing a comprehensive solution across "medicine - pharmaceuticals - insurance - patients" [2] Group 3 - During the reporting period, the company provided solutions to 127 top hospitals in China and 44 regulatory agencies and policymakers, covering over 10,000 hospitals in total [3] - The company utilized a dual-driven approach of "data elements × AI technology" to solidify its data intelligence foundation and accelerate the large-scale application of intelligent solutions [3] - The large model technology assisted multiple hospitals in upgrading their data governance and research platforms, with clinical research expanding into oncology, respiratory, and traditional Chinese medicine disciplines, while the doctor Copilot product matrix achieved full coverage of the diagnosis and treatment process, with over 50,000 uses in a single hospital [3]

Core Insights - The company reported total revenue of RMB 358.1 million for the six months ending September 30, 2025, representing an 8.7% year-on-year increase, driven by significant growth in its big data and health management platforms [1] - The company narrowed its losses to RMB 15.8 million, a 72.0% reduction compared to the previous year, while cash flow from operating activities saw a 56.0% year-on-year decrease in net outflow [1] - YiduCore, the company's core algorithm engine, has made significant advancements in developing large language models for the healthcare sector, processing over 13 billion patient records [2] Financial Performance - Total revenue reached RMB 358.1 million, with big data platform revenue increasing by 14.6% and health management platform revenue growing by 30.3% [1] - The company’s loss for the period was reduced to RMB 15.8 million, indicating improved operational efficiency [1] - Cash reserves totaled RMB 2.0993 billion, reflecting a strong liquidity position [1] Technological Advancements - YiduCore has trained its large language model using over 500 billion high-quality tokens and has built a dataset covering more than 98 specific diseases [2] - The company won multiple awards for its medical NLP capabilities, including first place in the healthcare track at the "Data Elements ×" competition [2] Market Engagement - The company provided solutions to 127 top hospitals and 44 regulatory bodies, covering over 10,000 hospitals in total [3] - The number of life sciences clients reached 88, with 17 out of the top 20 multinational pharmaceutical companies as clients [3] - The health management platform has maintained a leading position in core cities, with over 6.15 million insured under the "Shenzhen Hui Min Bao" program [3]

Core Insights - The article discusses the integration of interdisciplinary research in fields such as biology, chemistry, and computer science, highlighting its role in advancing digital medicine and healthcare services [2] - Despite the potential of technologies like artificial intelligence (AI) in biomedicine, their widespread application is hindered by technical barriers and limited expertise among physicians [2][5] - A recent study demonstrated that large language models (LLMs) can assist physicians in overcoming these technical challenges, although concerns about dependency and misinformation remain [3][6] Study Findings - A randomized controlled trial involving 64 primary ophthalmologists showed that the use of LLMs like ChatGPT-3.5 significantly improved project completion rates from 25% to 87.5% [5][7] - After a two-week washout period, 41.2% of successful intervention participants were able to complete new projects independently without LLM support [5][7] - The study identified potential risks associated with LLMs, including the tendency for physicians to rely on AI-generated information without full understanding [5][9] Implications - The findings suggest that LLMs can democratize medical AI research by helping physicians navigate design, execution, and reporting challenges [9] - However, the long-term risks of dependency on LLMs warrant further investigation to ensure safe and effective use in clinical settings [6][9]

截至2025年11月25日收盘，锦好医疗（920925）报收于31.13元，较前一交易日上涨0.81%，最新总市值 为30.65亿元。该股当日开盘31.03元，最高31.88元，最低30.81元，成交额达2010.52万元，换手率为 1.16%。 公司近日发布公告称，惠州市锦好医疗科技股份有限公司于2025年11月20日召开2025年第三次临时股东 会，会议审议通过《关于使用部分闲置自有资金购买银行理财产品的议案》。出席本次股东会的股东共 5人，代表有表决权股份总数的61.0135%，表决结果为同意股数占比100%，无反对和弃权情况。广东东 方昆仑（东莞）律师事务所对本次会议进行了见证，并出具法律意见书，认为本次股东会的召集、召开 程序合法合规，决议合法有效。 最新公告列表 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《2025年第三次临时股东会决议公告》 《广东东方昆仑(东莞)律师事务所关于惠州市锦好医疗科技股份有限公司2025年第三次临时股东 会法律意见书》 ...